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ABSTRACT
ANTICANCER EFFECT OF INDANONE-BASED THIAZOLYL HYDRAZONE
DERIVATIVE ON P53 MUTANT COLON CANCER CELL LINES: IN VITRO
AND IN VIVO STUDY
SILPA NARAYANAN
Colorectal cancer is the third leading cause of cancer related deaths in the United States.
Currently, irinotecan, a topoisomerase I inhibitor, is an important anticancer drug approved
for patients with advanced or recurrent colorectal cancer. Considering the low response
rate and the events of high toxicity caused by irinotecan, we evaluated a series of thirteen
thiazolyl hydrazone derivatives of 1-indanone for their potential antineoplastic activity and
four compounds showed promising anticancer activity against most of the tested colon
cancer cell lines with IC50 values ranging from 0.41 ± 0.19 to 6.85 ± 1.44 μM. It is
noteworthy that the compound, N-Indan-1-ylidene-N'-(4-Biphenyl-4-yl-thiazol-2-yl)hydrazine (ITH-6) is found to be more effective than irinotecan against p53 mutant colon
cancer cells, HT-29, COLO 205, and KM 12 than p53 wild-type colon cancer cell line such
as HCT 116. Mechanistic studies reveal that ITH-6 arrests these cancer cell lines in G2/M
phase of the cell cycle, induces apoptosis, and causes an increase in ROS level with a
significant reduction in the GSH level. The cell cycle arrest is related to the inhibition of
tubulin polymerization in the mitotic phase. Moreover, ITH-6 inhibits the expression of
NF-kB p65 and Bcl-2, which proves its cytotoxic action. The downregulation of NF-kB
p65 can be further proved by immunofluorescence. Moreover, CRISPR/Cas9 was applied
to establish NF-kB p65 gene knockout HT-29 cell model to validate the target of ITH-6.

In addition, ITH-6 significantly decreased tumor size, growth rate and tumor volume in
mice bearing HT-29 and KM 12 tumor xenografts. Overall, the results suggest that ITH-6
could be a potential anticancer drug candidate for p53 mutant colon cancers.
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CHAPTER 1. Introduction
Cancer remains the most intriguing disease of human populations in terms of its types,
progression and treatment(1–3). Despite of the advances in the field of cancer research and
translational medicine, which has indeed resulted in higher cure rates for various tumor
types, cancer remains the second leading health challenge, after heart related disorders in
both developing and developed countries(4,5). Among malignancies, colorectal cancer
(CRC) is the third most commonly diagnosed malignancy and the fourth leading cause of
cancer related deaths globally(6). CRC is considered to be an environmental disease,
affected by cultural, social and lifestyle practices(7). Studies done in the past have shown
that endocrine factors and obesity are the two major contributors to an increase in the risk
of CRC(8). Moreover, weight gain during the middle age and metabolic dysfunctions can
predispose to abdominal obesity which positively correlates with CRC(9). It has also been
found that the dietary habits influence the risk of CRC. The dietary fat especially from
animal sources has earlier been demonstrated to be metabolized into a carcinogen by
colonic flora(10). Moreover, the genetic makeup of individuals also plays an important role
in its genesis and mutations in chromosome 18q have resulted in errors in DNA replication
which account for 15–20% of sporadic colon cancer(11,12). According to the American
Cancer Society, around 104,610 CRC cases were diagnosed in 2020 in the United States
with around 53,200 deaths estimated from the disease(13). Studies have shown that
approximately 30% of CRC cases are hereditary in nature(14). The etiology remains
unknown for around 75% cases of CRC and the remaining small percentage of cases are
due to familial incidences or inflammatory bowel disease. Around 33% of familial cases
have a genetic basis(15). Surgery is the primary treatment option for most cases of
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CRC(16). The current pharmacological management of primary CRC is based on the drug
regimens such as FOLFOX and FOLFIRI for metastatic CRC. Though therapeutically
efficacious, these anticancer agents bear several side effects such as nausea, vomiting,
diarrhea, neurotoxicity, and infections which frequently reach to the level of causing a halt
of the treatment(17,18). Targeted specific drugs such as regorafenib, cetuximab, and
bevacizumab have now been approved as alternatives for the treatment of CRC(19,20).
Although these drugs are effective and increase the overall survival, the existence of drug
resistance mechanisms and toxicity remain serious concerns(21,22). Since previous studies
have established that the indanone ring exerts anticancer activity (23–26), here we
investigate the anticancer effects of a series of indanone-based thiazolyl hydrazones on
different human cancer cell lines.
1.1 Biological activities of indanones and related compounds
Indanones and related compounds are important bioactive molecules. These compounds
have been studied for various biological activities including cancer and Alzheimer’s type
of diseases(27). Indanone and its analogues are being developed to combat drug-resistant
malignancies(28).

Another indanone analogue, donepezil hydrochloride has been

approved by US-FDA for the treatment of mild to moderate Alzheimer’s disease. This drug
acts as an acetylcholinesterase inhibitor and some other indanones have been isolated from
natural products(29). Being such a useful moiety, several synthetic strategies have also
been developed for their synthesis. Extensive studies on bioactivity of indanone derivatives
open up more and more new possibilities of their applications as antiviral and antibacterial
agents(30), anticancer drugs(31), pharmaceuticals used in the Alzheimer’s disease
treatment(32), cardiovascular drugs(32), insecticides, fungicides, herbicides(33) and non-
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nucleoside, low molecular drugs for the hepatitis C treatment, which inhibit HCV
replication(34,35). Moreover, the derivatives of indanone are being developed to treat
drug-resistant malignancies in some cell lines i.e., KB403 (oral and mouth cancer cells),
WRL68 (liver cancer cells), CaCO2 (colon cancer cells), HepG2 (liver cells) and MCF7
(hormone-dependent breast cancer cells)(36).
1.2 Overview of NF-kB signaling pathway
The nuclear factor-kappa B (NF-kB) is a key regulator of inflammation and has been
associated with carcinogenesis(37). The NF-kB family is comprised of 5 subunits, RelA
(p65), RelB, NF-kB1 (p50 and its precursor p105), NF-kB2 (p52 and its precursor p100),
and c-Rel(38). There are two pathways for NF-kB activation, canonical and non-canonical
pathway. The canonical activation of the NF-kB signaling pathway by cytokines, such as
interleukin-1(IL-1) and tumor necrosis factor (TNF) stimulate the IkB kinase (IKK)
complex which causes the degradation of Inhibitor of Kappa Light Chain Gene Enhancer
in B Cells, Alpha (IkBα) by ubiquitin proteasome system and release the NF-kB subunits
into the nucleus where they become active and induce gene expression. The modulators
involved in the canonical pathway are IKKs including IKKα, IKKβ and IKKγ or NEMO.
The alternative pathway (non-canonical pathway) includes B-cell activation factor (BAFFR), lymphotoxin β-receptor (LTβR), and CF40 receptor activator for nuclear factor-kappa
B (RANK) which in turn activate adaptor protein NF-kB-inducing kinase (NIK) which
activates IKKα(39).
As indicated above, in unstimulated cells, NF-kB dimers are localized in the cytoplasm
through their association with IkB proteins. However, it has been reported that the complex
constituted by IkBα and the p50/p65 dimer can shuttle between the cytoplasm and the
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nucleus, although it remains transcriptionally inactive. Indeed, only after degradation of
IkB proteins, this dimer localizes to the nucleus and binds to DNA(40,41). Several IkB
proteins have been identified, including IkBα, IkBβ, IkBε, IkBκ, and B-cell lymphoma 3
(Bcl-3) (40,42). IkBα and IkBβ are the best known members of the IkB family, as they are
expressed in almost all tissues; conversely, the expression of IkBε, IkBζ, and Bcl-3 is
restricted to hematopoietic cells(41,42). The primary target of IkBα is the dimer p50/p65,
whereas IkBβ is associated mainly with p65/c-Rel dimers.
It has been reported that NF-kB activation in the intestinal epithelial cells has a key role
in tumor formation. NF-kB is a transcription factor which can regulate over 200 genes
those are involved in cell survival and inflammation(38). There is strong relation between
that inflammation and occurrence of CRC. NF-kB activation has a pro-inflammatory and
pro-tumorigenic roles (43).
1.3 Role of NF-kB in cancer
NF-kB signaling is involved in cellular immunity, inflammation, and stress, as well as
regulation of cell differentiation, proliferation, and apoptosis(44–48). The NF-kB pathway
is often altered in both solid and hematopoietic malignancies, promoting tumor-cell
proliferation and survival(49,50). Prolonged chronic inflammation may cause tissue
damage, degenerative diseases, and cancers of multiple types by inducing cellular stress,
recruiting inflammatory factors, and DNA damage. Moreover, chronic inflammation also
results in tumorigenesis by genetic mutations and epigenesis. (51). Inflammation increases
the risk of tumor formation by disabling the immune system from attacking tumor cells
and by inducing the cell proliferation and genetic instability that leads to oncogenic
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mutations. NF-kB is the regulator of inflammation and cancer. In cancerous cells with
elevated NF-kB activity, the accumulation of proinflammatory cytokines at the tumor site
promotes the pro-tumorigenic microenvironment. In patients with inflammatory bowel
disease (IBD), pro-tumorigenic cytokines such as TNF-α, IL-1, and IL-17 elevate NF-kB
activity which may increase the risk of colon cancer(52). Chronic inflammation can lead
to genomic instability and genetic mutations may favor tumor initiation and
development(53,54). At the site of inflammation, reactive oxygen species (ROS) are
released by neutrophils and macrophages and cause DNA damage which can activate the
NF-kB pathway and form a positive feedback loop to enhance NF-kB activity in different
types of cells at the site of inflammation. Furthermore, NF-kB induces the expression of
anti-apoptotic genes such as the caspase-8 inhibitor FLIP and members of the B-cell
lymphoma 2 (Bcl-2) family of apoptosis regulators. These evidences support the facts that
tumor cells may also depend on the NF-kB pathway to escape from apoptosis, which has
been identified as one of the essential hallmarks of cancer(51). Based on the results, it is
possible that the role of NF-kB in certain types of cancer and at certain stages of cancer
development is mainly through promoting cell proliferation rather than inhibiting
apoptosis.
1.4 p53 status and NF-kB
Regulation of cellular metabolism by NF-kB depends on the status of tumor suppressor
gene, p53, in the cells. This is one of the many aspects of the crucial crosstalk between NFkB and p53. Many oncogenic mutations, such as those in epidermal growth factor receptor
(EGFR), Ras, phosphoinositide 3-kinase (PI3K) and p53, contribute to NF-kB activation
in tumor cells. Kras and p53 mutations have been found in 20 -25% and in ~50% of all
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cancers, respectively, and the mutation rates are especially high in pancreatic, CRC and
lung cancers(55). The crosstalk between p53 and NF-kB has drawn much attention in the
cancer research community. As described above, wild-type p53 antagonizes NF-kB
function and suppresses tumorigenesis; about 50% of human cancers acquire p53 mutations
(or lose the wild-type allele) and thus activate the NF-kB pathway during tumor
development. The binding of transcription co-factor CBP to p53 or NF-kB decides a cell's
fate for apoptosis or survival(56). Furthermore, the NF-kB pathway is also involved in the
transcription of mouse double minute 2 (Mdm2), a key ubiquitin E3 ligase of p53, thus
indirectly regulating p53 protein stability(57). On the other hand, wild-type p53 may
suppress glucose intake and glycolysis by reducing glucose transporter 3 (GLUT3)
expression on the cell membrane(58). This may be one of the mechanisms by which wildtype p53 suppresses the NF-kB pathway to a basal level in untransformed cells. In other
words, p53 mutations prolong NF-kB activation in the presence of inflammatory stimuli.
For example, a recent study examined the correlation between nuclear p65 staining and
p53 mutation status in multiple head and neck squamous cell carcinomas and non-small
cell lung cancers (NSCLC). They found that mutant p53 overexpression correlates with
increased NF-kB activity and reduced apoptosis, while tumors harboring wild -type p53
have much less nuclear p65 staining(59). Furthermore, mice harboring a germline p53
mutation develop more severe chronic inflammation and persistent tissue damage in the
dextran sulfate sodium (DSS)-induced mouse colon cancer model. These mice are much
more prone to inflammation-associated colon cancer when compared to their p53 wild-type
counterparts(59).
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Moreover, in this study we explored the mechanisms of action of most active derivative
which caused the inhibition of colon cancer cells’ proliferation, produced cell cycle arrest,
and induced apoptosis, downregulate NF-kB p65 and Bcl-2. The effects of this derivative
on tubulin polymerization, production of reactive oxygen species (ROS), glutathione
depletion and anticancer activity in vivo were also determined.
1.5 NF-kB and Bcl-2
The Bcl-2 family of cell death regulators is critical for determining cell fate in the apoptotic
pathway. Bcl-2 and its mammalian homologs Bcl-x L, Bfl-1 (also called A1), and Mcl-1
block cell death, while Bax, Bcl-x S, Nbk (also called Bik), Bak, and Bad promote
apoptosis(60). Each of these factors influences the cleavage-mediated activation of
caspases, which act as the ultimate downstream effectors of the suicide program. Bcl-2related proteins were shown to block apoptosis in lymphoid cells under conditions in which
NF-kB activity was inhibited(61). This raised the possibility that some of these factors may
lie downstream of NF-kB in the survival cascade. The pro-survival Bcl-2 homolog Bfl-1
is transcriptionally controlled by Rel/NF-kB is consistent with these results(62–65).
Overexpression of members of the Bcl-2 family, such as A1 or Bfl1 and Bcl-xL, inhibit
the activation of caspase 9 or proapoptotic Bcl-2 family members produced by inducers of
the intrinsic pathway. Inducers of the intrinsic pathway include agents that caus e DNA
damage or oxidative stress. On the other hand, overexpression of the cellular inhibitors of
apoptosis (CIAPs) and Fas-associated death domain-like IL-1β-converting enzyme
inhibitor protein (FLIP) modulates the activation of caspase 8 produced by induction of
TNF receptor family members. Finally, NF-kB regulates the activation of caspases,
including caspases 3 and 7, which result from activation of both apoptotic pathways.
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A variety of different NF-kB pathway inhibitors have been developed and are undergoing
clinical studies in lymphomas and other malignancies. These include agents that block IKK
activity, IkB degradation, NF-kB nuclear targeting, or NF-kB target gene activity(66). The
current work provides further understanding of the relative contribution of NF-kB pathway
in cancer and its downstream target genes on the activation of each apoptotic pathway,
which is important for the design and assessment of novel targeted anticancer agents.

Graphical Abstract: NF-kB pathway in cancer and mechanism of anticancer activity
of ITH-6
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CHAPTER 2. Materials and methods
2.1 Chemicals and equipment
All thiazolyl hydrazone derivatives were synthesized at the University of Karachi, Pakistan
(Figure 2). Regorafenib was obtained from Bayer HealthCare Pharmaceuticals Inc.
(Whippany, NJ) and irinotecan hydrochloride from Alfa Aesar (Haverhill, MA). Stock
solutions (10 mM) of all the compounds in DMSO were prepared and a series of dilutions
were made. Figure 3A shows the chemical structure of ITH-6. Dulbecco’s modified
Eagle’s Medium (DMEM, IX), fetal bovine serum (FBS), Phosphate Buffer Saline (PBS),
10,000 IU/ml penicillin and 10,000 µg/ml streptomycin, and trypsin 0.25% were purchased
from Hyclone (Waltham, MA). 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium
bromide) (MTT), Dimethyl Sulfoxide (DMSO), and other chemicals were obtained from
Sigma-Aldrich Chemical Co (St. Louis, MO). Propidium Iodide (PI)/RNase staining buffer
was purchased from BD biosciences (SanJose, CA) and the apoptosis k it were purchased
from Biotium (Hayward, CA). 5-(and-6)-chloromethyl-20,7'-dichlorodihydrofluorescein
diacetate, acetyl ester (CM-H2DCFDA) was purchased from Molecular probes™ (Eugene,
OR). GSH kit from Abcam (Cambridge, MA) and HTS-Tubulin Polymerization Assay
Biochem Kit from Cytoskeleton (Denver, CO). Monoclonal antibodies D97JR (selective
against ALDH1A1), E7K2Y (against CD44), D14E12 (against NF-kB p65), E4Z1Q
(against topoisomerase I), D3R6Y (against procaspase-3), 44D4 (against IkBα) and 16H1
(against GAPDH), D5C9H (against TBP) and secondary anti-rabbit/mouse HRP linked
antibody were obtained from Cell Signaling (Danvers, MA). Alexa flour conjugated
secondary antibody was obtained from Molecular Probes (Eugene, OR). Trizol reagent was
obtained from Invitrogen Life Technologies (Carlsbad, CA). The NF-kB p65, IL-6, Bcl-2
9

and 18 S TaqMan gene expression kits and superscript IV reverse transcription kit were
obtained from Fisher Scientific (Waltham, MA).

2.2 Cell lines and cell culture
HEK293 (human embryonic kidney cell line), NIH/3T3 (mouse fibroblast cell line) and
human colon cancer cell lines (COLO 205, HCT-15, SW620, KM 12, HT-29, S1), SNB19 (human glioblastoma cell line), PC-3 (human prostate cancer cell line), NCI-H460
(human non-small lung cancer cell line), IGROV-1and SK-OV-3 (human ovarian cancer
cell lines), ABCB1-overexpressing cancer cell line, SW620/AD300, ABCG2overexpressing cancer cell line, S1-M1-80 and K-562 (human chronic myeloid leukemia
cell line) were used in this study. S1-M1-80 cells were grown in the DMEM medium which
has the anticancer drug, mitoxantrone, gradually increasing its concentration up to 80
µg/ml, inducing the overexpression of the ABCG2 transporter(67). SW620/AD300 cells
were maintained in complete medium with 300 ng/ml of doxorubicin(68). SW620,
SW620/AD300 and S1, S1-M1-80 cell lines were obtained from Dr. Susan E. Bates
(Columbia University, New York). All other cell lines were purchased from American
Type Culture Collection (ATCC) (Manassas, VA). The cell lines were cultured at 37°C,
5% CO2 with DMEM containing 10% FBS and 1% penicillin/streptomycin.
2.3 Experimental animals
Male athymic NCR (nu/nu) nude mice (age 5–6 weeks) were purchased from Taconic
Farms (Albany, NY) and were used for the animal study. The animals were kept under
alternate light/dark cycles, provided with food and water, and kept in polycarbonate cages
(4 mice/cage). The mice were housed at the St. John’s University Animal Care Center and
10

were regularly watched for tumor growth by measuring the size using Vernier calipers. The
animal protocol was approved by the St. John’s University’s Institutional Animal Care &
Use Committee (IACUC). The research was carried out in compliance with the Animal
Welfare Act and the U.S. Health Service.
2.4 Cell proliferation assay
The anticancer effects of ITH-6, regorafenib and irinotecan were determined by a 3-(4,5dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) calorimetric assay. Cells
were cultured, counted, and seeded onto 96 well plates with a cell density of 6×10 3 cells
per well. Following 24 h incubation, the cells were treated with different drugs (ranging
from a concentration of 0-30 µM). After 68 h, 20 µl of 4 mg/ml MTT, was added to each
well and the plates were further incubated 37˚C for 4 h. Subsequently, the MTT was
removed from all wells and 100 µl of DMSO was added to dissolve the formazan crystals
formed by the reduction of MTT in the mitochondria of the viable cells. The optical density
(OD) was measured at 570 nm by an Opsys microplate reader (Dynex technologies, VA).
2.5 Cell cycle analysis
Based on the cytotoxic effects of ITH-6, the cell cycle analysis was carried out on colon
cancer cell lines HT-29, COLO 205, and KM 12. The cells were treated with ITH-6 at three
different concentrations (0.3, 1 and 3 µM) for 24 h and the cell cycle analysis was
performed as described previously. In brief, the cells were harvested and centrifuged at 800
rpm for 5 min. The supernatant was removed and the cell pellet was washed with 1X PBS.
The cells were fixed overnight in ice cold 70% ethanol at 4˚C. The fixed cells were stained
with 50 µg/ml PI and 100 µg/ml of RNase at 37˚C for 30 min in the dark. The flow
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cytometric analysis was performed and the percentage of cells in different phases of cell
cycle were determined (G0/G1, S, G2/M).
2.6 Tubulin polymerization assay
The action of the test compound, ITH-6 on the tubulin polymerization was assessed by
tubulin polymerization kit. The preparation of samples and assay protocol was carried out
as per manufacturer’s instructions. ITH-6 (100 µM) was used a test compound while
paclitaxel and colchicine (10 µM) were used as controls.
2.7 Apoptosis analysis
The cells were incubated with ITH-6 for 24 h at concentrations of 0.3, 1 and 3 µM. After
24 h, the cells were washed, harvested, and stained with FITC-labeled annexin-V and PI at
37˚C for 30 min. The degree of apoptosis was measured at FL-1 and FL-2 of the flow
cytometer.
2.8 Intracellular ROS measurement
In order to investigate the effects of ITH-6 on the intracellular levels of ROS, the cells were
treated with ITH-6 at different concentrations ranging from 0 to 3 µM for 24 h. After 24 h,
the cells were washed and harvested. Subsequently, 10 µM of CM-H2DCFDA was added.
The CM-H2DCFDA dye enters into the cells, gets converted into the fluorescent (5chloromethyl-20-7’-dichlorofluorescein (DCF)) product by the action of intracellular
peroxides. The cells were incubated in dark at 37˚C for 30 min. Intracellular ROS levels
were measured using the flow cytometer.
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2.9 Intracellular GSH assay
In order to better understand the inverse relation between oxidative stress and GSH, the
colon cancer cell lines were treated with ITH-6 at different concentrations 0.3, 1, and 3
µM for 24 h. The intracellular GSH was measured using GSH assay kit and the protocol
was carried out as per manufacturer’s instructions. The samples were prepared and
analyzed as per manufacturer’s protocol using FL-1 of flow cytometer.
2.10 Western blot analysis
Western blot analysis was performed to detect the expression level of Aldehyde
Dehydrogenase 1 Family Member A1 (ALDH1A1), a cell surface adhesion receptor
protein (CD44), a subunit of nuclear factor kappa light chain enhancer of activated B cells
(NF-kB p65) (nuclear and cytoplasmic), procaspase-3, topoisomerase I (TOP 1) and IkBα
(nuclear and cytoplasmic) proteins after incubating HT-29, COLO 205 and KM 12 cells
with different concentrations, 0.3, 1 and 3 µM of ITH-6 for 72 h. Cell lysates were prepared
by adding lysis buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS) to all the three different cell lines. The nuclear and
cytoplasmic proteins were separated using NE_PER Nuclear and Cytoplasmic Extraction
Reagent Kit (Fisher Scientific). Protein (40 µg) was then resolved by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto
polyvinylidene fluoride (PVDF) membranes through electrophoresis. Subsequently , PVDF
membranes were blocked with 5% non-fat milk dissolved in TBST buffer (10 mmol·L−1
Tris-HCL, 150 mmol·L−1 NaCl and 0.1% Tween20 pH 8.0) for 2 h at room temperature.
The samples were incubated with primary antibodies against NF-kB p65 (nuclear and
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cytoplasmic), ALDHA1, CD44, IkBα (nuclear and cytoplasmic), procaspase-3, TOP I
protein (1:1000) and housekeeping genes, GAPDH and TBP (1:1000) overnight at 4°C and
then incubated with peroxidase-conjugated secondary antibodies (1:1000) for 2 h at room
temperature. The reaction was visualized by means of enhanced chemiluminescence
detection reagents (Amersham, NJ) using the manufacturer’s protocol(19). The resulting
protein bands were analyzed using Image J software.
2.11 mRNA expression
HT-29, COLO 205 and KM 12 cancer cells were incubated with 0.3, 1 and 3 M of ITH6 for 72 h and total RNA was extracted using the RNA extraction trizol reagent as
previously described(69). RNA was quantified using Nanodrop and RNA samples with a
A260/280 ratio in the range of 1.8 to 2.0 were chosen. These samples were subjected to
reverse transcription and the cDNAs formed (by superscript IV reverse transcription kit)
were used for quantitative PCR. This analysis was performed using the NF-kB p65, Bcl-2,
IL-6 and 18S TaqMan gene expression assay kits. The PCR data were quantitated using
the ∆∆Ct method and presented as relative - fold of mRNA expression.
2.12 Immunofluorescence
The immunofluorescence assay was performed as previously described(19). Briefly, after
being cultured overnight in 24-well plates, cells (2 ×10 4/well) were treated with ITH-6 (0.3,
1 and 3 µM) for 72 h. Then, cells were fixed in 4% paraformaldehyde for 10 min and
permeabilized by 0.1% Triton X-100 for 10 min before being blocked with 6% BSA at
37°C for 1 h. The presence of NF-kB p65 was determined using monoclonal antibody
(dilution 1:1000) for incubation at 4°C overnight. Cells were washed with iced PBS after
each incubation time. Alexa Fluor 594 (Ex = 561 nm, Em = 617 nm) conjugated secondary
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antibody (1:1000) was used after washing with ice cold PBS. DAPI (Ex = 345 nm, Em =
455 nm) was used to counterstain the nuclei. The cells were washed with ice -cold PBS
before being imaged. Immunofluorescence images were collected using an EVOS FL Auto
fluorescence microscope from Life Technologies Corporation (Gaithersburg, MD).

2.13 Cytotoxicity of ITH-6 on ABCB1 and ABCG2 overexpressing cell lines.
The cytotoxicity assay was conducted in a 96 well plate usin g parental (SW620 and S1)
and drug-resistant (SW620/AD300 and S1-M1-80) cell lines that were seeded at a density
of 6×10 3 cells/well. Following 24 h incubation, the cells were treated with ITH-6 (ranging
from a concentration of 0-100 µM). After 68 h, the absorbance was measured at 570 nm
using spectrophotometer as previously described(70,71) and IC50 values were calculated.
2.14 Knockout of NF-kB p65 gene in HT-29 cells
A CRISPR/Cas9 system was used to construct the NF-kB p65 gene knockout subline of
HT-29 cells. The custom-designed mammalian CRISPR vector was obtained from Vector
Builder Inc. (Chicago, IL). The transfection of the NF-kB p65 targeting vector into HT-29
cells was conducted using Fugene6 transfection reagent (Promega, Madison, WI)
according to the manufacturer's instructions. Briefly, HT-29 cells were seeded in 100 mm
dishes with 1 × 10 6 cells per dish and cultured overnight in DMEM with 10% FBS without
antibiotics. Then, 10 μg of plasmid DNA was prepared in 376 μl of Opti-MEM medium
and mixed with 24 μl of Fugene 6 reagent. Followed by a 30 min incubation at room
temperature, the complex was mixed into the cell culture medium and incubated with the
cells in a culture incubator for 48 h. At the end of incubation, the transfected cells were
rinsed with PBS then incubated with the selection medium containing 2 mg/ml G418 for 3
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days. Non-transfected cells were used as negative controls for the selection process. Single
colonies of survived cells were obtained and expanded for further study. The knockout of
NF-kB p65 was further verified by measuring protein expression using Western blotting
and by cell viability study using MTT.
2.15 Molecular modeling
Macintosh Operating System (OS Sierra) with Mac Pro 6-core Intel Xenon E5 processor
system was used to perform docking experiments using the Maestro v12. 3. 012 software
(Schrödinger, LLC, New York, NY, USA, 2019) software. Lig-prep was used for ITH-6
ligand preparation(72). The heterodimer protein model was imported from the Protein data
bank. ‘Protein Preparation Wizard’ was used for protein preparation. The grid generation
was done by selecting residues at 20 Å distance from bound inhibitors in the model protein
(1IKN)(73,74). The residues selected were: 26, 28, 29, 30, 49, 50, 181, 222, 224, 225, 236,
237, 238, 239, 241, 258, 259, 260, 261, 275. Extra Precision docking was performed with
maximum 10 poses(75).
2.16 Nude mouse MDR xenograft model
The colon cancer cells, HT-29 and KM 12 xenograft mouse models were established as
previously

reported(76).

The

cells

were

implanted

subcutaneously

into

immunocompromised mice under the left and right armpit regions, respectively. When the
tumors reached a diameter of around 0.5 cm (day 0) after one week, the mice were
randomized into four treatment groups consisting of 6 mice per group as follows: (a)
polyethylene glycol 300 as the vehicle which was given orally (q3d × 7), (b) irinotecan (30
mg/kg, q3d × 7) was given intraperitoneally (i.p.), dissolved in normal saline(77) (c) ITH6 (3 mg/kg) was diluted in PEG 300 and given orally (q3d × 7), and (d) ITH-6 (6 mg/kg)
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group was diluted in PEG 300 and given orally (q3d × 7). The treatment was given for
twenty-one days and the body weights were recorded every third day to calculate the drug
dosage. Tumor volumes (calculated using the two diameters of tumors, termed A and B)
were calculated every third day using vernier calipers and calculated using the following
formula, V=π/6(A+B/2)3 (78,79). The blood was taken via submandibular puncture on the
last treatment day and white blood cells (WBC) and platelets counts were determined in all
four groups.
At the end of the treatment regimen, the mice were euthanized, and the tumors were
removed and weighed.
2.17 Collection of plasma and tumor tissues
In separate experiments, mice bearing HT-29 and KM 12 tumors were separated into three
groups: (i) mice receiving 3 mg/kg ITH-6 orally (ii) 6 mg/kg ITH-6 orally and (iii) 30
mg/kg i.p. irinotecan. Animals were anesthetized with 3 % isoflurane and 50 µL of blood
was collected 5, 30, 60, 120,180 and 240 min after the appropriate treatment, by
submandibular puncture into heparinized tubes. In addition, the tumors were excised,
weighed, and stored at - 80°C for further study.
2.18 HPLC protocol for plasma sample collection
To the collected plasma samples 500 ml methanol: TFA (10:1) mixture was added and it
was incubated on ice for 30 min to allow protein precipitation. It was then centrifuged at
15000 rpm at 4⁰ C for 20 min. The supernatant was collected and filtered through 0.2 mm
filter into HPLC vials and then the samples were analyzed using HPLC.
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2.19 HPLC protocol for tumor sample collection
The tumors were homogenized in 10 ml PBS. The homogenized mixture was extracted
using 10 ml diethyl ether. The mixture was centrifuged at 4⁰ C at 1,500 rpm for 10 min
and then the diethyl ether layer was collected. The solvent was evaporated, and the
residue was redissolved in 500 ml methanol: TFA (10:1) mixture. It was incubated on ice
for 30 min to allow protein precipitation. It was then centrifuged at 15,000 rpm at 4⁰C for
20 min. The supernatant was collected and filtered through 0.2 mm filter into HPLC vials
and then the samples were analyzed using HPLC.
2.20 HPLC method.
The Agilent 1260 infinity series was used to analyze the samples. The ACE C18 column
with dimensions 5 mm x 250 x 4.6 mm was used. The solvent system used was A= water
(with 0.1% formic acid) and B= methanol (with 0.1% formic acid). The injection volume
used was 100 µl and the detector wavelength used was 254 nm.
Method for Irinotecan: Flow rate: 0.5 ml/min
Time (min)
0
10
12
15

Solvent A percentage
60
98
98
60

Solvent B percentage
40
2
2
40

Method for ITH-6: Flow rate: 0.5 ml/min
Time (min)
0
20
22
25

Solvent A percentage
60
98
98
60

Solvent B percentage
40
2
2
40

The tR (retention time) for irinotecan was 6.2 min and t R for ITH-6 was 17.5 min.
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The standard curve was created based on dosage. Irinotecan (2 mg/ml, 1mg/ml, 0.5
mg/ml, 0.25 mg/ml, 0.125 mg/ml, 0.625 mg/ml) and ITH-6 (1mg/ml, 0.5 mg/ml, 0.25
mg/ml, 0.125 mg/ml, 0.625 mg/ml, 0.313 mg/ml).
2.21 Statistical analysis
All experiments were repeated at least three times and the differences were determined
using a one-way analysis of variance (ANOVA). The statistical significance was
determined at p < 0.05. The post hoc analysis was performed using Tukey’s test. The data
were analyzed using GraphPad Prism, version 6.
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CHAPTER 3. Results
3.1 Non-cytotoxic effect of ITH-6 on normal cell lines.
To determine the cytotoxic effect of ITH-6 on normal healthy cell lines, MTT was carried
against human embryonic kidney cell line, HEK293 and mouse fibroblast cell, NIH/3T3.
ITH-6 did not show any cytotoxicity on these cell lines and IC 50 values were more than 30
µM (Table 1).
3.2 ITH-6 inhibits cell proliferation in colon cancer cell lines
In order to determine the cytotoxicity of synthesized compounds on colon cancer cell
lines, MTT assay was performed against different cancer cell lines (as mentioned in cell
lines and cell culture). The IC50 values were >10 µM against all cancer cell lines other
than colon cancer cell lines (Table 2). Among all compounds, four compounds exhibited
remarkable cytotoxic activities against most of the tested colon cell lines (Table 3). For
the five types of tested human colorectal adenocarcinoma cells, SW620, COLO 205, KM
12 and HT-29 cells, ITH-1 had cytotoxic effects, with IC50 values of >10 µM, 1.37 µM,
2.50 µM, and 0.86 µM, respectively. Also, ITH-3 had cytotoxicity on the same colon
cancer cell lines with IC50 value of >10 µM, 2.64 µM, 2.91 µM, and 1.99 µM,
respectively. The IC50 of ITH-6 on HT-29, COLO 205, and KM 12 cell lines (Figure 3B)
were 0.40, 0.98 and 0.41 µM, respectively. The IC50 was more than 10 µM on HCT-15
cell line. For ITH-12, IC50 of 2.14 µM on COLO 205, 2.90 µM on KM 12 and 1.17 µM
on HT-29 cells were exhibited. IC50 values of regorafenib on HT-29, COLO 205 and KM
12 were 22.7 µM, 9.43 µM and 5.02 µM, respectively (Figure 3C). Irinotecan has IC50
values of 8.49 µM, 22.84 µM and 23.15 µM on HT-29, COLO 205, and KM 12 cells
(Figure 3D). These results indicate that ITH-6 has a significant effect on the cell viability
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of HT-29, COLO 205 and KM 12 cells compared to the other cell lines, suggesting that
the drug is more potent to p53 mutant colon cancer cells and chosen for the detailed study
of its possible mechanism.
3.3 ITH-6 arrests the colon cancer cells in the G2/M phase of the cell cycle.
In order to investigate the mechanisms by which ITH-6 inhibits the proliferation of colon
cancer cells, its effects on the progression of cell cycle were studied. On treatment with
ITH-6 (0.3, 1, and 3 µM), a concentration dependent increase in the percentage of cells in
G2/M phase of the cell cycle of all the three cell lines was observed. The concentrations
were selected based on the IC 50 values. ITH-6 increased the percentage of cells from 37.5%
to 72.1% in HT-29 (Figure 4A), 15.1% to 33.4% in COLO 205 (Figure 4B), and 24.1% to
77.8% in KM 12 cells (Figure 4C). These results suggest that ITH-6 arrests the cells in
G2/M phase with negligible effect on other phases of cell cycle in all the three cell lines.
3.4 ITH-6 inhibits tubulin polymerization in the mitotic phase
To further elucidate the mechanisms by which ITH-6 arrests the colon cancer cells in
G2/M phase of the cell cycle, tubulin polymerization assay was performed according to
the manufacturer's protocol. The test drug (ITH-6) was compared against control drugs,
paclitaxel, and colchicine. Our results indicated that paclitaxel (10 µM) stabilizes the
microtubule by enhancing the tubulin polymerization for a period of 1 h while colchicine
(10 µM) acted as a tubulin polymerization inhibitor. Interestingly, ITH-6 at 100 µM
inhibited the tubulin polymerization, thus suggesting that ITH-6 acted on the G2/M phase
of the cell cycle by inhibiting the tubulin polymerization activity, an effect like
colchicine, however, less potent than colchicine (Figure 5).
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3.5 ITH-6 induces apoptosis in colon cancer cells
To understand the apoptotic effects of ITH-6 on colon cancer cell lines, the cells were
treated at different concentrations (0.3, 1, and 3 µM) of ITH-6 for 24 h. In all the three cell
lines, most of the cells were viable in the control group and no apoptosis was observed.
ITH-6 exhibited a concentration dependent increase in the early and late apoptosis of HT29 (Figure 6A), COLO 205 (Figure 6B), and KM 12 (Figure 6C) cells.
3.6 ITH-6 elevates ROS production in colon cancer cells
Since an increase in intracellular ROS is a measure of induction in apoptosis, we
investigated the effects of ITH-6 on the intracellular ROS production. The cells were
treated at the indicated concentrations for 24 h and the intracellular ROS levels were
measured using the flow cytometer. As shown in the Figure 7A, ROS percentage increased
from 5.98% (control) to 66.30% (ITH-6 at 3 µM) in HT-29, 1.88% (control) to 71.70%
(ITH-6 at 3 µM) in COLO 205 (Figure 7B), and 4.26% (control) to 69.57% (ITH-6 at 3
µM) in KM 12 (Figure 7C) cells. These results suggested that ITH-6 elevates intracellular
ROS levels and causes apoptosis in colon cancer cells.
3.7 ITH-6 inhibits GSH levels in colon cancer cells
Since a decrease in GSH levels is known to induce ROS and in turn induce apoptosis, the
effects of ITH- 6 on the intracellular GSH levels were determined at the indicated
concentrations. Our results showed that ITH-6 exhibited a concentration-dependent
decrease in intracellular GSH levels. As shown in Figure 8A, the GSH percentage
decreased from 93.80% (control) to 23.70% (ITH-6 at 3 µM) in HT-29, from 96.80%
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(control) to 34.90% (ITH-6 at 3 µM) in COLO 205 (Figure 8B), and from 91.30% (control)
to 7.81% (ITH-6 at 3 µM) in KM 12 cells (Figure 8C).
3.8 The effect of ITH-6 on the expression level of different targets associated with
apoptosis of colon cancer cells.
To figure out the mechanism of the cytotoxicity of the test compound ITH-6, we performed
the Western blotting experiment on various proteins. The proteins selected were
ALDH1A1, CD44, NF-kB p65 (nuclear and cytoplasmic), procaspase-3, TOP 1 and IkBα
(nuclear and cytoplasm) as they are important prognostic markers in colon cancer cells.
HT-29, COLO 205 and KM 12 cells were incubated with 0.3, 1 and 3 µM of ITH-6 for 72
h. At a concentration of 3 µM, ITH-6 downregulated the nuclear NF-kB p65 expression in
HT-29 (Figure 10A and C) and COLO 205 (Figure 11A and C) cells compared to the
control whereas in KM 12 cells, the test compound at concentrations of 0.3, 1 and 3 µM
significantly decreased the nuclear NF-kB p65 expression level compared to the positive
control, resveratrol (20 µM) and KM 12 cells are more sensitive to NF-kB p65
downregulation following the treatment with ITH 6 (Figure 12A and C). There was no
change in the cytoplasmic NF-kB p65 protein expression in all cell lines treated with ITH6 (Figure 10, 11 and 12B, D).
Moreover, there was no change in the expression of ALDH1A1 and CD44 (Figure 9), TOP
1 (Figure 13, 14 and 15 C and E) and IkBα (cytoplasmic) levels (Figure 13, 14 and 15 B
and D). There was a concentration-dependent decrease in the procaspase-3 expression in
COLO 205 and KM 12 (Figure 14 and 15C and F) cells treated with ITH-6 at 3 different
concentrations, 0.3, 1 and 3 µM for 72 h whereas in HT-29, there was no change in the
expression of procaspase-3 after incubating with ITH-6 (Figure 13C and F). Hence, we can
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summarize that the possible mechanism behind ITH-6 induced cytotoxicity in these colon
cancer cells results from downregulating nuclear NF-kB p65 protein expression.
3.9 The effect of ITH-6 on the mRNA level of NF-kB p65, IL-6 and Bcl-2 in colon
cancer cell lines.
The incubation of HT-29, COLO 205, and KM 12 cancer cell lines with 0.3, 1 and 3 µM
of ITH-6 for 72 h remarkably decreased the NF-kB p65 protein expression compared to
cells incubated with vehicle. Furthermore, quantitative real-time PCR (RT-PCR)
experiments demonstrated that the treatment of these cells with the ITH-6 for 72 h
remarkably decreased NF-kB p65 mRNA expression (Figure 16A, B and C).
It was previously indicated that NF-kB p65 transcriptionally regulates IL-6 and Bcl-2, antiapoptotic proteins(80). Hence, RT-PCR was performed to evaluate the effect of ITH-6 on
IL-6 (Figure 17A, B and C) and Bcl-2 (Figure 18A, B and C) mRNA levels and showed
that treatment with ITH-6 downregulated the Bcl-2 expression thereby further proving the
role of ITH-6 on the apoptosis of these colon cancer cell lines.

3.10 Immunofluorescence
Immunofluorescence experiment was conducted to find out if ITH-6 can downregulate
the expression of nuclear NF-kB p65 in HT-29 (Figure 19), COLO 205 (Figure 20), and
KM 12 (Figure 21) cells when they are treated with ITH-6 for a period of 72 h. Our results
indicated that incubating these colon cancer cells with ITH-6 decreased NF-kB p65
expression which is consistent with the Western blot and RT-PCR results.
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3.11

Interaction analysis of ITH-6-NF-kB p65 docked complex

The previously reported IkBα/NF-kB crystal model (PDB code: 1IKN) was used for
docking analysis. Stimulation between ITH-6 and the heterodimer complex was
performed using induced fit docking. The docking position of ITH-6 showed XP docking
score of -5.7 kcal mol-1, which shows good binding affinity. Figure 22A depicts the
docking pose and interaction between ITH-6 and the IkBα/NF-kB heterodimer protein.
Figure 22B shows H- bonding between the thiazolidine hydrogen and the carbonyl
oxygen of GLY259. The biphenyl ring resides in the pocked formed by amino acids:
GLN 26, LYS 28, GLN 29, ARG 30, whereas the indene ring sits in the pocked made by
amino acids: ARG 236, GLY 237, SER 238, PHE 239, GLN 241.
3.12

ITH-6 is not susceptible to ABCB1- and ABCG2-mediated drug resistance

An MTT assay was performed to examine the susceptibility of ITH-6 to MDR mediated
by ABCB1 and ABCG2 transporters. Herein, resistance fold (RF) was used to evaluate if
there is any degree of change in the resistance to ITH-6 resulting from the presence of
ABCB1or ABCG2. Based on the results, there was no significant difference in the IC 50
values of ITH-6 in the ABCB1 overexpressing SW620/AD300 cell line (Figure 23A) and
ABCG2 overexpressing S1-M1-80 cell line (Figure 23B) relative to their corresponding
parental cell lines.
3.13 Knockout of NF-kB p65 gene in HT-29 cells
The knockout of NF-kB p65 gene in HT-29-NF-kB p65ko cells was verified by the NFkB p65 protein expression using Western blotting (Figure 24A). The expression level of
NF-kB p65 in HT-29-NF-kB p65ko cells was remarkably low compared to that of HT-29
cells (Figure 24B).
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To further verify the change in gene expression by targeting NF-kB p65 using the
CRISPR/Cas9 system in HT-29-NF-kB p65ko cells, MTT assay was performed.
Resistance fold (RF) was used to evaluate if there is any degree of change in the IC 50
values resulting from the absence of NF-KB p65 expression. Based on the results, the
IC50 value in HT-29-NF-kB p65ko cells is around 180-fold higher than that of the
corresponding HT-29 cell lines (Figure 24C).
3.14 The effect of ITH-6 and irinotecan in mice with HT-29 and KM 12 tumor
xenografts
The colon cancer cell lines, HT-29 and KM 12 were implanted subcutaneously and over a
period of 7 to 10 days, the mice developed visible tumors and subsequently, the treatment
regimen was started. The mice implanted with HT-29 and KM 12 cells had a significant
reduction in volume (Figure 24 and 25B) and weight (Figure 24 and 25C) of the tumor
after treatment with an oral dose of ITH-6 6 mg/kg compared to the positive control, 30
mg/kg irinotecan which was given intraperitoneally (Figure 24 and 25A). Importantly, the
doses that we administered suggested that the treatment did not produce significant overt
toxicity as there was no mortality or a significant decrease in body weight (Figure 26A)
and no significant change in blood cell count (Figure. 26B and C).
3.15 Concentration of ITH-6 and irinotecan in the tumor and plasma
The plasma level of irinotecan (intraperitoneally) was gradually decreasing as time
increases (Figure 27B) and for ITH-6 (given orally), plasma concentration was gradually
increasing and reached a peak at 60 min and then decreased (Figure 27A). However, the
tumor concentration of irinotecan (30 mg/kg) was less compared to ITH-6 (6 mg/kg)
(Figure 28).
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Table 1. The effect of ITH-6 on normal cell lines
Compound

HEK 293

NIH/3T3
IC50 (µM)

ITH-6

>30

>30

μM-Micromole.
The cytotoxic effects of the test compounds on HEK293 (human embryonic kidney cells)
and NIH/3T3 (mouse fibroblast cells).
Values in Table 1 are representative of at least three independent experiments performed
in triplicates.
IC50: concentration that inhibits cell survival by 50% (mean ± SD).
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Table 2: The effect of synthesized compounds on different cancer cell lines.
CELL LINES

Compounds
N-Indan-1-ylidene-N'-[4-(4-methoxyphenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(3,
5Dichloro-phenyl)-thiazol-2-yl]hydrazine
N-Indan-1-ylidene-N'-[4-(4-Bromophenyl)-thiazol-2-yl]-hydrazine

Code
ITH-1

SNB19

PC-3

NCIH460

IGRO
V-1

SKOV-3

K-562

IC50 (µM)
> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

> 10

ITH-2

ITH-3

N-Indan-1-ylidene-N'-[4-(4-ChloroITH-4
phenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(3-nitroITH-5
phenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-(4-Biphenyl-4ITH-6
yl-thiazol-2-yl)-hydrazine
N-Indan-1-ylidene-N'-(4-phenylITH-7
thiazol-2-yl)-hydrazine
N-Indan-1-ylidene-N'-[4-(3-BromoITH-8
phenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(4-nitro-phenyl)- ITH-9
thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(2-hydroxyITH-10
phenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(2,4-Dichloro- ITH-11
phenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(4-methylITH-12
phenyl)-thiazol-2-yl]-hydrazine
N-Indan-1-ylidene-N'-[4-(3-FluoroITH-13
phenyl)-thiazol-2-yl]-hydrazine

µM-Micromole
IC50: concentration of the drug that inhibits cell survival by 50%
The cytotoxic effects of test compounds on SNB-19 (human glioblastoma cell line), PC-3
(human prostate cancer cell line), NCI-H460 (human lung cancer cell line), IGROV-1
(human ovarian cancer cell line), SK-OV-3 (human ovarian cancer cell line), and K-562
(human chronic myeloid leukemia cell line).
Values in Table 2 are representative of at least three independent experiments performed
in triplicates.
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Table 3: The effect of synthesized compounds on colon cancer cell lines.
CELL LINES
Compou
nds

HCT 116

COLO
205

Code
ITH-1
ITH-2
ITH-3
ITH-4
ITH-5
ITH-6
ITH-7
ITH-8
ITH-9
ITH-10
ITH-11
ITH-12
ITH-13

HCT15

SW620

KM 12

HT-29

IC50 (µM)
5.04±1.06

1.37±0.29

>10

>10

>10

>10

>10

>10

1.25±0.02

2.64±0.35

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

5.04±0.20

0.98±0.06

>10

6.85±1.44

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

>10

2.14±0.36

>10

>10

>10

>10

>10

>10
µM-Micromole

2.50±0.30 0.86±0.17
>10

>10

2.91±0.17 1.99±0.29

0.41±0.19 0.44±0.06

2.90±0.06 1.17±0.27
>10

>10

IC50: concentration of drug that inhibits cell survival by 50% (mean ± SD).
The cytotoxic effects of the test compounds on HCT 116, COLO 205, HCT-15, SW620,
KM 12, and HT-29 (human colon cancer cell lines).
Values in Table 3 are representative of at least three independent experiments performed
in triplicates.
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Figure 1 NF-kb pathway
(Adapted from NF-kB in Cancer: A Matter of Life and Death. Aggarwal and Sung. Cancer
Discovery, 2011).
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Figure 2

Figure 2. The schematic representation of ITH-6 synthesis from the parent
compound, 1-indanone.
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Figure 3

Figure 3. Chemical structure of N-Indan-1-ylidene-N'-(4-Biphenyl-4-yl-thiazol-2-yl)hydrazine (ITH-6) and cytotoxicity of ITH-6, Regorafenib and Irinotecan in HT-29,
COLO 205, and KM 12 cell lines. (A)The chemical structure of ITH-6 was drawn using
Chem Draw. Survival fraction (%) was measured after treatment with (B) ITH-6, (C)
Regorafenib and (D) Irinotecan for 72 h in HT-29 (orange), COLO 205 (blue), and KM
12 (grey) cell lines. Points with error bars represent the mean ± SD for independent
determinations in triplicates. The figure 3B, 3C and 3D are representative of three
independent experiments.
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Figure 4

Figure 4. Effect of ITH-6 on the cell cycle of HT-29, COLO 205, and KM 12 cell
lines. (A) HT-29, (B) COLO 205, and (C) KM 12 cells were treated with ITH-6 (24 h) in
a concentration-dependent manner, stained with propidium iodide (PI), and analyzed by
flow cytometer. Quantification of the PI staining data is presented as the percentage of
distribution through stages of the cell cycle: blue-G0/G1; red- S; green- G2/M. Points
with error bars represent the mean ± SD for independent determinations in triplicates.
The figures are representative of three independent experiments. * p < 0.05, ** p < 0.01,
*** p < 0.001, and **** p < 0.0001 compared to the control group.
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Figure 5

Figure 5. Effect of ITH-6 on the tubulin polymerization. The tubulin polymerization
assay was performed as per manufacturer’s protocol. The change in optical density (OD)
at 340 nm was plotted against time in min for ITH-6 at 100 μM (green) was compared with
control (blue), paclitaxel at 10 μM (orange), and colchicine at 10 μM (yellow). Points with
error bars represent the mean ± SD for independent determinations in triplicates. The figure
is a representative of three independent experiments.
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Figure 6

Figure 6. Effect of ITH-6 on the apoptosis of HT-29, COLO 205, and KM 12 cell lines.
(A) HT-29, (B) COLO 205, and (C) KM 12 cells were treated with ITH-6 (24 h) in a
concentration-dependent manner, stained with Annexin-V and PI, and analyzed by flow
cytometer. The apoptotic cell population was quantified by flow cytometry. Bar graphs in
blue represents live cells, in red represents cells undergoing apoptosis, and in gr een
represents cell undergoing necrosis. Bar graphs represents average cell population of three
independent experiments and error bars represents SD for independent determinations in
triplicates. ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to the control group.
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Figure 7

Figure 7. Effect of ITH-6 on the ROS production in HT-29, COLO 205, and KM 12
cell lines. (A) HT-29, (B) COLO 205, and (C) KM 12 cells were treated with ITH-6 (24
h) in a concentration-dependent manner as mentioned in “Materials and methods”. Points
with error bars represent the mean ± SD for independent determinations in triplicates. The
figures are representative of three independent experiments.* p < 0.05, ** p < 0.01 and ***
p < 0.001 compared to the control group.
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Figure 8

Figure 8. Effect of ITH-6 on the GSH levels of HT-29, COLO 205, and KM 12 cell
lines. The GSH assay was performed as per manufacturer’s protocol. (A) HT-29, (B)
COLO 205, and (C) KM 12 cells were treated with ITH-6 (24 h) in a concentrationdependent manner as mentioned in “Materials and methods”. Points with error bars
represent the mean ± SD for independent determinations in triplicates. The figures are
representative of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001 compared to the control group.
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Figure 9

Figure 9. Effect of ITH-6 on the expression of ALD1HA1 and CD44: The effect of
ITH-6 on the expression of ALDHA1 and CD44 on (A) HT-29 (B) COLO 205 and (C)
KM 12 cells were tested after the cells were treated with 0.3, 1 and 3 µM of ITH-6 for 72
h. Relative quantification of the effect of ITH-6 on (D) CD44 in HT-29 and ALDH1A1 in
(E) COLO 205 and (F) KM 12 cells. The expression levels of the target proteins were
normalized to GAPDH. Equal amounts of total cell lysates were used for each sample
and a Western blot analysis was performed. The figures are representative of three
independent experiments.
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Figure 10

Figure 10. Effect of ITH-6 on the expression of (A)nuclear and (B) cytoplasmic
fraction of NF-kB p65 protein on HT-29 cells. The effect of ITH-6 on the expression of
nuclear and cytoplasmic fraction of NF-kB p65 protein was tested after the cells were
treated with 0.3, 1 and 3 μM of ITH-6 for 72 h. Relative quantification of the effect of ITH6 on (C) nuclear and (D) cytoplasmic fraction of NF-kB p65 in HT-29 cells. The expression
level of NF-kB p65 protein was normalized to TBP (nucleus) and GAPDH (cytoplasm).
Equal amounts of total cell lysates were used for each sample and a Western blot analysis
was performed. The figures are representative of three independent experiments. * p < 0.05
compared to the control group
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Figure 11

Figure 11. Effect of ITH-6 on the expression of (A) nuclear and (B) cytoplasmic
fraction of NF-kB p65 protein on COLO 205 cells. The effect of ITH-6 on the
expression of nuclear and cytoplasmic fraction of NF-kB p65 protein was tested after the
cells were treated with 0.3, 1 and 3 μM of ITH-6 for 72 h. Relative quantification of the
effect of ITH-6 on (C) nuclear and (D) cytoplasmic fraction of NF-kB p65 in COLO 205
cells. The expression level of NF-kB p65 protein was normalized to TBP (nucleus) and
GAPDH (cytoplasm). Equal amounts of total cell lysates were used for each sample and a
Western blot analysis was performed. The figures are representative of three independent
experiments. * p < 0.05 compared to the control group.
Figure 12
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Figure 12. Effect of ITH-6 on the expression of (A) nuclear and (B) cytoplasmic
fraction of NF-kB p65 protein on KM 12 cells. The effect of ITH-6 on the expression of
nuclear and cytoplasmic fraction of NF-kB p65 protein was tested after the cells were
treated with 0.3, 1 and 3 μM of ITH-6 for 72 h. Relative quantification of the effect of ITH6 on (C) nuclear and (D) cytoplasmic fraction of NF-kB p65 in KM 12 cells. The
expression level of NF-kB p65 protein was normalized to TBP (nucleus) and GAPDH
(cytoplasm). Equal amounts of total cell lysates were used for each sample and a Western
blot analysis was performed. The figures are representative of three independent
experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to the control group.
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Figure 13

Figure 13. Effect of ITH-6 on the expression of (C) Topoisomerase I and
Procaspase-3 and (A) nuclear and (B) cytoplasmic expression of IkBα on HT-29
cells. The effect of ITH-6 on the expression of Topoisomerase I, Procaspase-3 and IkBα
(nuclear and cytoplasmic) was tested after the cells were treated with 0.3, 1 and 3 μM of
ITH-6 for 72 h. Relative quantification of the effect of ITH-6 on (D) cytoplasmic IkBα,
(E) Topoisomerase I and (F) Procaspase-3 in HT-29 cells. The expression levels of the
target proteins were normalized to TBP (nucleus) and GAPDH (cytoplasm). Equal
amounts of total cell lysates were used for each sample and a Western blot analysis was
performed. The figures are representative of three independent experiments.
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Figure 14

Figure 14. Effect of ITH-6 on the expression of (C) Topoisomerase I and
Procaspase-3 and (A) nuclear and (B) cytoplasmic expression of IkBα on COLO 205
cells. The effect of ITH-6 on the expression of Topoisomerase I, Procaspase-3 and IkBα
(nuclear and cytoplasmic) was tested after the cells were treated with 0.3, 1 and 3 μM of
ITH-6 for 72 h. Relative quantification of the effect of ITH-6 on (D) cytoplasmic IkBα,
(E) Topoisomerase I and (F) Procaspase-3 in COLO 205 cells. The expression levels of
the target proteins were normalized to TBP (nucleus) and GAPDH (cytoplasm). Equal
amounts of total cell lysates were used for each sample and a Western blot analysis was
performed. The figures are representative of three independent experiments.
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Figure 15

Figure 15. Effect of ITH-6 on the expression of (C) Topoisomerase I and
Procaspase-3 and (A) nuclear and (B) cytoplasmic expression of IkBα on KM 12
cells. The effect of ITH-6 on the expression of Topoisomerase I, Procaspase-3 and IkBα
(nuclear and cytoplasmic) was tested after the cells were treated with 0.3, 1 and 3 μM of
ITH-6 for 72 h. Relative quantification of the effect of ITH-6 on (D) cytoplasmic IkBα,
(E) Topoisomerase I and (F) Procaspase-3 in KM 12 cells. The expression levels of the
target proteins were normalized to TBP (nucleus) and GAPDH (cytoplasm). Equal
amounts of total cell lysates were used for each sample and a Western blot analysis was
performed. The figures are representative of three independent experiments. * p < 0.05
compared to the control group.
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Figure 16

Figure 16. Effect of ITH-6 on NF-kB p65 expression at mRNA level on (A) HT-29,
(B) COLO 205, and (C) KM 12 cells. The effect of ITH-6 on NF-kB p65 mRNA
expression was tested after the cells were treated with 0.3, 1 and 3 µM of ITH-6 different
concentrations for 72 h. Points with error bars represent the mean ± SD for independent
determinations in triplicates. The figures are representative of three independent
experiments. * p < 0.05 and ** p < 0.01 compared to the control group.
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Figure 17

Figure 17. Effect of ITH-6 on IL-6 expression at mRNA level on (A) HT-29, (B)
COLO 205, and (C) KM 12 cells. The effect of ITH-6 on IL-6 mRNA expression was
tested after the cells were treated with 0.3, 1 and 3 µM of ITH-6 different concentrations,
for 72 h. Points with error bars represent the mean ± SD for independent determinations
in triplicates. The figures are representative of three independent experiments. * p < 0.05
compared to the control group.
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Figure 18

Figure 18. Effect of ITH-6 on Bcl-2 expression at mRNA level on (A) HT-29, (B)
COLO 205, and (C) KM 12 cells. The effect of ITH-6 on Bcl-2 mRNA expression was
tested after the cells were treated with 0.3, 1 and 3 µM of ITH-6 different concentrations,
for 72 h. Points with error bars represent the mean ± SD for independent determinations
in triplicates. The figures are representative of three independent experiments. ** p <
0.01, *** p < 0.001 and **** p < 0.0001 compared to the control group.
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Figure 19

Figure 19. Immunofluorescence experiment on NF-kB p65 expression on HT-29 cells
followed by treatment with ITH-6. HT-29 cells were incubated for 72 h with 0.3, 1 and
3 µM of ITH-6. The red color represents the presents of NF-kB p65 and the blue color
represents the nucleus.
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Figure 20

Figure 20. Immunofluorescence experiment on NF-kB p65 expression on COLO 205
cells followed by treatment with ITH-6. COLO 205 cells were incubated for 72 h with
0.3, 1 and 3 µM of ITH-6. The red color represents the presents of NF-kB p65 and the blue
color represents the nucleus.
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Figure 21

Figure 21. Immunofluorescence experiment on NF-kB p65 expression on KM 12 cells
followed by treatment with ITH-6. KM 12 cells were incubated for 72 h with 0.3, 1 and
3 µM of ITH-6. The red color represents the presents of NF-kB p65 and the blue color
represents the nucleus.
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Figure 22.

Figure 22. Molecular interaction of ITH-6 with the human NF-kB model. (A)
Docking pose of ITH-6 within the binding pocket of IkBα/NF-kB heterodimer. The
protein is represented as multicolored ribbons. Amino acid residues are shown as follows:
nitrogen in blue, hydrogen in white, carbon in gray, and oxygen in red. The ligand is
represented by the ball and stick model with carbon atoms are represented in carbon in
green, nitrogen in blue, hydrogen in white and sulfur in yellow. the yellow dashes
represent the hydrogen bonding. (B) 2-D ligand interaction between ITH-6 and IkBα/NF-
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kB heterodimer. Magenta arrow represents hydrogen bonding with amino acid residues
within 5 Å of the ligand.

Figure 23

Figure 23. Cytotoxicity of ITH-6 on ABCB1- and ABCG2-overexpressing cell lines.
Survival fraction (%) was measured after treatment with ITH-6 (µM) for 72 h on (A)
SW620, SW620/AD300 and (B) S1, S1-M1-80 cell lines. Points with error bars represent
the mean ± SD for independent determinations in triplicates. The figures are
representative of three independent experiments.
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Figure 24

Figure 24. NF-kB p65 gene knockout in HT-29 cells (A)Western blotting result of NFkB p65 protein expression level and (B) relative quantification of NF-kB p65 in HT-29
and HT-29-NF-kB p65ko cells. The expression level of the target protein was normalized
to GAPDH. (C) Survival fraction (%) was measured after treatment with ITH-6 (µM) for
72 h on HT-29 and HT-29-NF-kB p65ko cells. Points with error bars represent the mean
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± SD for independent determinations in triplicates. The figures are representative of three
independent experiments. ** p < 0.01 compared to the control group.

Figure 25

Figure 25. ITH-6 inhibits HT-29 tumor growth, volume, and weight in xenograft
mouse model. NCR nude mice were inoculated with subcutaneous implantation of HT-29
cells. During a 21 days treatment period, ITH-6 (6 mg/kg) significantly inhibited the (A)
growth, (B) volume and (C) weight of HT-29 tumor xenografts compared to the vehicle
control and irinotecan group. Values represent the median ± SD of 6 animals per group.
Similar results were obtained in 2 independent experiments. * p < 0.05 and ** p < 0.01
compared to the control group.
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Figure 26

Figure 26. ITH-6 inhibits KM 12 tumor growth, volume, and weight in xenograft
mouse model. NCR nude mice were inoculated with subcutaneous implantation of KM 12
cells. During a 21 days treatment period, ITH-6 (6 mg/kg) significantly inhibited the (A)
growth (B) volume and (C) weight of KM 12 tumor xenografts compared to the vehicle
control and irinotecan group. Values represent the median ± SD of 6 animals per group.
Similar results were obtained in 2 independent experiments. * p < 0.05 and ** p < 0.01
compared to the control group.
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Figure 27

Figure 27. (A) Changes in mean body weight before and after treatment for xenograft
model are shown. (B) The changes in mean white blood cells in nude mice (n = 6) at the
end of the 21-day treatment period and (C) the changes in mean platelets in nude mice (n
= 6) at the end of the 21-day treatment period.
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Figure 28

Figure 28. Plasma irinotecan and ITH-6 concentrations in xenograft mouse model
The plasma concentrations at different time points, 5, 30, 60-, 120-, 180- and 240-min
following administration of (A) ITH-6 (3 and 6 mg/kg) given orally and (B) irinotecan (30
mg/kg) given intraperitoneally.
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Figure 29

Figure 29. Intratumoral concentrations of irinotecan and ITH-6 in KM 12 (n=6) and
HT-29 tumors (n=6). Points with error bars represent the mean ± SD.
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CHAPTER 4. Discussion
Despite of the advances in chemotherapy, the mortality rate of CRC is quite alarming.
Patients with CRC fall into two categories; ones in which the disease is confined to the
primary site of origin (Dukes’A and B) and the other where it spreads to the regional lymph
nodes (Dukes’C and D). The first category of patients can be surgically cured while for the
later ones, surgery has is only palliative role and survival rate is less than 30%(81). The
drugs already approved and being used for the treatment of colon cancer include irinotecan,
oxaliplatin, capecitabine and the targeted drugs include bevacizumab, ramucirumab etc.
Irinotecan, approved by the USFDA in 1996, is a prodrug which is converted into its active
metabolite, SN-38 inside the body. It has long been used as the first line therapy for patients
with recurrent and metastatic CRC however, the dose related toxicities such as vomiting,
dehydration, myelosuppression, alopecia, and diarrhea are a serious concern(82).
Bevacizumab, a humanized monoclinal antibody was approved by the USFDA in 2004 for
the treatment of patients with advanced CRC. Bevacizumab exhibits some rare serious
adverse

effects such

as

bowel perforation, arterial

embolic

events,

and

leukoencephalopathy (83–85).
In the present study, we find that the compound ITH-6 has lower IC50 values on the colon
cancer cell lines, HT-29, COLO 205, and KM 12 as compared to the conventional
anticancer drug, irinotecan. Indanone and its derivatives are well known for their wide
range of biological activity(28). Studies done in the past have shown that the indanone
derivative are potent anti-inflammatory, analgesic, antimicrobial, anticholinergic,
anticancer, and antimalarial agents. 3-aryl substituted indanone analog was found
significantly active against the HeLa and K562 cell lines(86). The other derivatives, gallic
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acid based indanone analogs are cytotoxic (IC 50 of 0.01 µM) on breast cancer cell lines
MCF-7 and MDA-MB-231(36). In addition, 2-substituted indanone analogs are active
against non-small lung cancer cell line(87) and 5,6-dimethoxy-1-indanonederivative is
significantly cytotoxic on multidrug resistant cell lines, MCF-7/ADR, MES-SA/DX5 and
HL-60/ADR(28). The present indanone derivative, ITH-6 exhibited IC50 values of 0.44
µM, 0.98 µM, and 0.41 µM on HT-29, COLO 205, and KM 12 cell lines respectively. The
IC50 of regorafenib and irinotecan on HT-29, COLO 205, and KM 12 cell lines (22.7 µM,
9.43 µM and 5.02 µM for regorafenib and 8.49 µM, 22.84 µM and 23.15 µM for irinotecan)
has shown that ITH-6 exhibited lower IC50 as compared to the newer drugs, regorafenib
and irinotecan. The difference in response to different colon cancer cell lines are due to
their establishment from different origin and p53 mutation status. Inhibition of the cell
proliferation has long been known to be associated with the changes in the cell cycle (88).
The alterations in the cell cycle progression cause tumor growth and proliferation. It has
been stated that anticancer drugs can arrest the cells in various phases of cell cycle and
inhibit the tumor growth(89). Our cell cycle results indicate that ITH-6 arrest the cells in
G2/M phase and the maximum effect is at high concentration (3 µM) and there is no
significant effect on other phases of cell cycle. These cell cycle results show that the test
compound is G2/M phase specific. This instigated the idea to investigate the effects of
ITH-6 on tubulin polymerization and mitotic spindle formation, two processes that take
place in G2/M phases of cell cycle. The tubulin polymerization assay results show that
ITH-6 at 100 µM inhibits tubulin polymerization for 1 h. Paclitaxel (Taxol), a well-known
anticancer drug, stabilizes the microtubule against depolymerization, and is hence known
as polymerization enhancer(90). Colchicine on the other hand, inhibits the microtubule
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polymerization and is thus known as a polymerization inhibitor(91). We compared the
tubulin polymerization effects of ITH-6 to that of paclitaxel and colchicine and found that,
like colchicine, ITH-6 inhibited the tubulin polymerization. However, the extent of
inhibition was not significantly comparable.
Since the cell cycle arrest is related to apoptosis, an apoptotic analysis was carried out using
HT-29, COLO 205, and KM 12 cell lines. In all the three cell lines, a substantial number
of apoptotic cells were observed in the lower and upper right quadrants, which are the
representatives of early and late apoptosis. The results showed an increase in early and late
apoptosis in these cell lines with maximum apoptosis seen at the highest concentration of
3 µM. Cellular studies have shown that an increase in the level of ROS causes an oxidative
stress which results in oxidative damage to the cellular components(92). It enters into the
cells, gets converted into the fluorescent (5-chloromethyl-20-7’-dichlorofluorescein
(DCF)) product by the action of intracellular peroxides, hence, the ROS analysis is
conducted in all the cell lines(93,94). We found that ITH-6 at the highest concentration (3
µM) induced intracellular ROS production in HT-29, COLO 205, and KM 12 cell lines.
The mitochondrial GSH maintains the integrity of mitochondrial proteins and lipids and
modulates ROS production. Oxidative damage is associated with an increase in
mitochondrial ROS production and a decrease in GSH which in turn triggers apoptosis(95).
Therefore, intracellular GSH assay was performed in all the three colon cancer cell lines.
A significant decrease in GSH levels was also observed with compound ITH-6 in all the
three cell lines with the maximum decrease at the highest concentration of 3 µM. Given
that the cytotoxicity on colon cancer cells could have resulted from an inhibition of some
specific proteins related to the apoptotic pathway, we conducted Western blotting and RT61

PCR experiments to determine the mechanism of ITH-6. One of the targeted proteins, NFkB p65 is a key mediator in inflammation and cancer. Many indanone derivatives which
are anticancer agents are proven to downregulate the expression of NF-kB p65 protein. Our
results indicated that the incubation of the HT-29, COLO 205, and KM 12 cancer cells with
3 µM of ITH-6 for 72 h significantly decreased the expression of the nuclear fraction of
NF-kB p65 protein compared to cells incubated with vehicle and the downregulation is
more predominant compared to 20 µM of the positive control, resveratrol. There was no
significant change in the cytoplasmic level of NF-kB p65 protein (inactive form which is
bound to IkBα). The NF-kB p65 subunit exists in an inactive state in the cytoplasm(96–98)
and when stimulated by molecules such as TNFα, or other cell stressors, leads
phosphorylation of IkBα, and subsequently results in IkB ubiquitination and degradation.
Once degraded, the remaining NF-kB p65 translocates to the nucleus, where it binds to the
DNA sequence of various target genes which regulate cell proliferation (99). ITH-6 acts
only on the nuclear fraction of NF-kB p65 thus proving it is downregulating the active form
of NF-kB p65 protein which plays a role in the cytotoxicity of ITH-6 on these cell lines.
Moreover, there was no significant change in the levels of ALDH1A1, CD44, IkBα
(nuclear and cytoplasmic), TOP I protein upon treatment with ITH-6.
The effect of ITH-6 may be either on transcriptional or translational level. The incubation
of HT-29, COLO 205, and KM 12 cancer cells at various concentrations of ITH-6 for 72 h
remarkably decreased the mRNA level of NF-kB p65 compared to cells incubated with
vehicle. There was a significant reduction in the mRNA expression of Bcl-2, which is an
anti-apoptotic protein and a downstream molecule of NF-kB pathway and overexpression
of Bcl-2 is common in a variety of cancers and has been shown to confer resistance to the
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apoptotic effect of chemo- and radiotherapy(100). Consequently, we performed in vitro
immunofluorescent experiments after treating the cells with the test compound, ITH-6 for
a period of 72 h. Our results showed that incubation with ITH-6 for a time point of 72 h
decreased NF-kB p65 expression which is consistent with the Western blot and mRNA
expression results. Furthermore, cytotoxicity assays on ABCB1- and ABCG2overexpressing cell lines showed that there was no significant difference in the IC 50
values of ITH-6 and it proved that it is not a substrate of ABCB1 or ABCG2 transporter.
The results from the gene knockout studies suggested that the NF-kB p65 gene knockout
in HT-29-NF-kB p65ko cell line can be useful in investigating whether ITH-6 induced
cytotoxicity is related to the downregulation of the target, NF-KB p65 which is highly
expressed in p53 mutant colon cancers.
Finally, based on our in vitro results, we conducted preclinical studies to determine the
effect of the anticancer effect of ITH-6 on tumor growth in athymic nude mice implanted
with HT-29 and KM 12 cells. The oral administration of 6 mg/kg of ITH-6 remarkably
attenuated the tumor growth in mice compared to mice treated with irinotecan (30 mg/kg
i.p.). Meanwhile, there was no notable change in body weight, WBC, and platelets count,
suggesting that ITH-6 can be tolerated at this dose and may be a promising candidate for
treating p53 mutant colon cancers. Furthermore, the anticancer efficacy of ITH-6 is better
than the positive control, irinotecan which can be further proved by its increased tumor
concentration compared to irinotecan. Our in vivo results suggest that ITH-6 has a
significant anticancer activity in mice with HT-29/KM 12 cancer cell xenografts at a dose
that does not produce significant toxic effects.
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CHAPTER 5. Conclusion
Anticancer drug discovery and development are considered as the grand challenges for
the pharmaceutical industry. Extremely dynamic mitotic-spindle microtubules indeed
remain the most successful and promising targets for anticancer therapy. Microtubulestabilizing agents are continually playing an important role in anticancer drug discovery
and development. In this study, we have shown that ITH-6 is an effective cytotoxic agent
against p53 mutant colon cancer cells and exhibits a better cytotoxic effect compared to
other drugs approved for colon cancer. Mechanistically, ITH-6 inhibits tubulin
polymerization, alters the cell cycle progression, and induces apoptosis by elevating the
intra cellular ROS and decreasing the intracellular GSH levels. It also downregulates the
expression of the NF-kB p65 and Bcl-2 in these cell lines which further proves its role in
the cytotoxicity of colon cancer cell lines. ITH-6 at a dose of 6 mg/kg p.o., did not produce
any observable toxic effects in the in vivo tumor xenografted mice during the treatment
period. It significantly decreased tumor size, growth rate and tumor volume in mice bearing
HT-29 and KM 12 tumor xenografts, compared to irinotecan. Together with its mechanism
of action, ITH-6 could be a potential anticancer drug candidate for p53 mutant CRC
treatment.
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